Article
Cohort profile: a nationwide study in Dutch CHEK2 c.1100delC families using the infrastructure of the HEreditary Breast and Ovarian cancer study Netherlands - Hebon-CHEK2.
BMJ open - 9 Oct 2024
Schreurs Maartje A C, Adank Muriel A, Hollestelle Antoinette, de Groot Rosa, Stommel-Jenner Denise J, Van Asperen Christi J, Ausems Margreet G E M, Berger Lieke P V, Blok Marinus J, van Engelen Klaartje, Hogervorst Frans B L, Geurts-Giele Willemina, Gille Johan J P, Wevers Marijke R, Schmidt Marjanka K, Hooning Maartje J
Abstract excerpt
PURPOSE: CHEK2 c.1100delC is associated with an increased breast cancer risk in women. While this variant is prevalent in the Netherlands (1% in the general population), knowledge of aetiology and prognosis of breast cancer and other tumours in CHEK2 c.1100delC carriers is lacking. The nationwide HEreditary Breast and Ovarian cancer study the Netherlands (Hebon) cohort aims to answer study questions in families...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.